ArticleLeukemia2019
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia.
Registry-linked trialAbstract read
In one paragraph
Article in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06414681 (An Open Label Pilot Trial of the Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined), which is not on this map. Cited by 57 papers.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT06414681 early_phase1recruitingnot on this mapstarted 2025, after this paper: background citation
An Open Label Pilot Trial of the Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
Who cites it
57 citing papers in PubMed, 94 citations in OpenAlex.
- Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?Leukemia · 2026Trial
- Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study.Blood neoplasia · 2025Trial
- The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.BMC cancer · 2022Trial
- Article
- The histopathological differential diagnosis of BPDCN and other plasmacytoid dendritic cell proliferations.Virchows Archiv : an international journal of pathology · 2026Review
- Chronic Myelomonocytic Leukemia: History, Pathobiology, Diagnostic Controversies, and Evolving Classification.Current hematologic malignancy reports · 2026Review
- An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study.Cancer science · 2026Article
- Plasmacytoid dendritic cell proliferations, malignant histiocytic (macrophage/dendritic cell) neoplasms and follicular dendritic cell neoplasms: report from the 2024 Joint CSHP/EA4HP/SH workshop.Virchows Archiv : an international journal of pathology · 2025Article
- Quantitative assessment of innate myeloid cells in myelofibrosis: insights into myeloid and plasmacytoid dendritic cell depletion and disease progression.Annals of hematology · 2025Article
- Article
- Plasmacytoid dendritic cell clusters are associated with poor prognosis in chronic myelomonocytic leukemia.Virchows Archiv : an international journal of pathology · 2025Article
- Practical diagnostic approach to assess myeloid and precursor cell neoplasms on trephine bone marrow biopsies: reflection of middle European reality.Journal of hematopathology · 2025Review
- The Role of Inflammation in CMML Pathobiology and Progression.Current hematologic malignancy reports · 2025Review
- Acute myeloid leukemia with plasmacytoid dendritic cell proliferation: A case report and literature review.Oncology letters · 2025Article
- Chronic Myelomonocytic Leukemia Microenvironment in Disease Progression and Therapy: Focus on Stepwise Reconfiguring of Myeloid-Immune Cell Interactions Driving Immune Tolerance.Current hematologic malignancy reports · 2025Review
- New leads to enhance tagraxofusp efficacy in pDC-AML.Blood neoplasia · 2025Article
- Case report: single-cell transcriptome sequencing reveals the clonal origin of mature plasmacytoid dendritic cell proliferation in early T-cell precursor lymphoblastic leukemia.Annals of hematology · 2025Article
- Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations.Haematologica · 2025Review
- Diagnostic approach to blastic plasmacytoid dendritic cell neoplasm: historical perspectives and current understanding.Journal of clinical and experimental hematopathology : JCEH · 2025Review
- Ulcerating skin lesions from blastic plasmacytoid dendritic cell neoplasm responding to low-dose radiotherapy-a case report and literature review.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 7 institutions in 2 countries.
Nolwenn LucasINSERM U1170, Gustave Roussy Cancer Center, Villejuif, France.
Matthieu DuchmannINSERM U1170, Gustave Roussy Cancer Center, Villejuif, France.ORCID http://orcid.org/0000-0002-7299-4572
Philippe RameauINSERM US23, CNRS UMS3655 Gustave Roussy Cancer Center, Villejuif, France.
Floriane NoëlINSERM U932, Institut Curie, PSL Research University, Paris, France.
Paula MicheaINSERM U932, Institut Curie, PSL Research University, Paris, France.
Véronique SaadaDepartment of Hematology, Gustave Roussy Cancer Center, Villejuif, France.ORCID http://orcid.org/0000-0001-8021-9050
Olivier KosmiderInserm U1016, CNRS UMR8104, Institut Cochin, Université Paris Descartes, Paris, France.
Gérard PierronINSERM US23, CNRS UMS3655 Gustave Roussy Cancer Center, Villejuif, France.
Martin E Fernandez-ZapicoSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA.
Matthew T HowardSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA.
Rebecca L KingSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA.
Sandrine NiyongereMalignant Hematology Department, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
M'boyba Khadija DiopINSERM U1170, Gustave Roussy Cancer Center, Villejuif, France.ORCID http://orcid.org/0000-0002-7849-4405
Pierre FenauxDepartment of Hematology, Hopital Saint Louis, Universite Paris Diderot, Paris, France.
Raphael ItzyksonDepartment of Hematology, Hopital Saint Louis, Universite Paris Diderot, Paris, France.
Christophe WillekensINSERM U1170, Gustave Roussy Cancer Center, Villejuif, France.
Vincent RibragINSERM U1170, Gustave Roussy Cancer Center, Villejuif, France.
Michaela FontenayInserm U1016, CNRS UMR8104, Institut Cochin, Université Paris Descartes, Paris, France.ORCID http://orcid.org/0000-0002-5492-6349
Eric PadronMalignant Hematology Department, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Vassili SoumelisINSERM U932, Institut Curie, PSL Research University, Paris, France.
Nathalie DroinINSERM U1170, Gustave Roussy Cancer Center, Villejuif, France.ORCID http://orcid.org/0000-0002-6099-5324
Mrinal M PatnaikDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. Patnaik.Mrinal@mayo.edu.ORCID http://orcid.org/0000-0001-6998-662X
Eric SolaryINSERM U1170, Gustave Roussy Cancer Center, Villejuif, France. eric.solary@gustaveroussy.fr.
Centre National de la Recherche Scientifique · FRInserm · FRMayo Clinic · USDélégation Paris 7 · FRMoffitt Cancer Center · USUniversité Paris-Sud · FRInstitut Gustave Roussy · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Islands of CD123
Indexed as
AgedAged, 80 and overAntigens, CDBiomarkersBone MarrowDendritic CellsFemaleHumansLeukemia, Myelomonocytic, ChronicMaleMembrane ProteinsPrognosisT-Lymphocytes, RegulatoryAntigens, CDBiomarkersflt3 ligand proteinMembrane Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT06414681ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.